Savara, Inc. - Common Stock (NQ:SVRA)

5.830 +0.340 (+6.19%)

Streaming Delayed Price Updated: 1:42 PM EDT, Jul 21, 2026 Add to My Watchlist

Price and Volume

Volume	1,425,073
Open	5.510
Bid (Size)	5.830 (200)
Ask (Size)	5.840 (2,200)
Prev. Close	5.490
Today's Range	5.470 - 6.025
52wk Range	2.260 - 7.005
Shares Outstanding	114,066,080
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline ↗

June 27, 2026

This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share gains.

Via The Motley Fool

Savara Announces New Employment Inducement Grant

June 12, 2026

From Savara Inc.

Via Business Wire

Performance

YTD	+3.4%	+3.4%
1 Month	+2.5%	+2.5%
3 Month	+3.9%	+3.9%
6 Month	-2.3%	-2.3%
1 Year	+154.6%	+154.6%

More News

Savara Announces Chief Financial and Administrative Officer Transition

June 08, 2026

From Savara Inc.

Via Business Wire

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

May 27, 2026

From Savara Inc.

Via Business Wire

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗

May 23, 2026

Via The Motley Fool

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗

May 23, 2026

Via The Motley Fool

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

May 20, 2026

From Savara Inc.

Via Business Wire

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

May 19, 2026

From Savara Inc.

Via Business Wire

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

May 18, 2026

From Savara Inc.

Via Business Wire

Savara Reports First Quarter Financial Results and Provides Business Update

May 12, 2026

From Savara Inc.

Via Business Wire

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

May 11, 2026

From Savara Inc.

Via Business Wire

Savara Announces New Employment Inducement Grant

April 17, 2026

From Savara Inc.

Via Business Wire

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

April 15, 2026

From Savara Inc.

Via Business Wire

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

April 14, 2026

From Savara Inc.

Via Business Wire

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

April 07, 2026

From Savara Inc.

Via Business Wire

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

March 30, 2026

From Savara Inc.

Via Business Wire

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

March 13, 2026

From Savara Inc.

Via Business Wire

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

March 06, 2026

From Savara Inc.

Via Business Wire

Savara Announces Participation in 2026 Citizens Life Sciences Conference

March 04, 2026

From Savara Inc.

Via Business Wire

SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy ↗

February 20, 2026

Via Stocktwits

Get insights into the top gainers and losers of Friday's after-hours session. ↗

February 20, 2026

Via Chartmill

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

February 20, 2026

From Savara Inc.

Via Business Wire

Savara Announces New Employment Inducement Grant

February 13, 2026

From Savara Inc.

Via Business Wire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

February 04, 2026

From Savara Inc.

Via Business Wire

Frequently Asked Questions

Is Savara, Inc. - Common Stock publicly traded?

Yes, Savara, Inc. - Common Stock is publicly traded.

What exchange does Savara, Inc. - Common Stock trade on?

Savara, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Savara, Inc. - Common Stock?

The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market

What is the current price of Savara, Inc. - Common Stock?

The current price of Savara, Inc. - Common Stock is 5.830

When was Savara, Inc. - Common Stock last traded?

The last trade of Savara, Inc. - Common Stock was at 07/21/26 01:42 PM ET

What is the market capitalization of Savara, Inc. - Common Stock?

The market capitalization of Savara, Inc. - Common Stock is 665.01M

How many shares of Savara, Inc. - Common Stock are outstanding?

Savara, Inc. - Common Stock has 665M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.